One institution who have a policy of restricting Deferiprone to patients with severe SS and continuing bleeds have found unclear evidence of benefit and a high rate of neutropaenic sepsis amounting to 40% of patients so treated. Has this lack of benefit been found by others? Or could the restriction of treatment to patients with severe SS symptoms and continuing bleeding result in such findings?